PATENT CLAIM ANALYSIS

Application Number: 15743349
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.

Claim (Index 98):
The dsRNA agent of  claim 96 , wherein the sense and antisense nucleotide sequences are selected from the group consisting of the sense and antisense nucleotide sequences of AD-66722, AD-66748, AD-66746, AD-66747, AD-66733, AD-66752, AD-66739, AD-66738, AD-66725, AD-66740, AD-66750, AD-66729, AD-66745, AD-66749, AD-66720, AD-66724, AD-66726, AD-66766, AD-66761, AD-66755, AD-66751, AD-66719, AD-66727, AD-66744, AD-66760, AD-66753, AD-66721, AD-66716, AD-66743, and AD-66728.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 86.0
- Lexical Diversity: 1.67442
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15399820', '14976261', '14947025', '14650128', '15670132']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8370097567670834
- 35 USC 102 Novelty (BERT): 0.5470253360227524
- Combined Prediction Score: 0.8080113146926504
- Mean Citation Score: 412.498488
- Max Citation Score: 416.99576
- Similarity Product: 255.66385032231327

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test